How to buy Trillium Therapeutics stock (TRIL)

Trillium Therapeutics is a biotechnology business based in the US. Trillium Therapeutics shares (TRIL) are listed on the NASDAQ and all prices are listed in US Dollars. Trillium Therapeutics employs 33 staff and has a trailing 12-month revenue of around $43,000.

Our top picks for where to buy Trillium Therapeutics stock

Buy Trillium Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Trillium Therapeutics stock price (NASDAQ: TRIL)

Use our graph to track the performance of TRIL stocks over time.

Trillium Therapeutics shares at a glance

• Key figures

Information last updated 2022-01-16.

52-week range	$0.00 - $0.00
50-day moving average more info button	$17.71
200-day moving average more info button	$11.96
Wall St. target price	$23.41
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.54

Is it a good time to buy Trillium Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Trillium Therapeutics financials

Revenue TTM	$43,000
Gross profit TTM	$148,000
Return on assets TTM	-12.74%
Return on equity TTM	-21.67%
Profit margin	0%
Book value	$2.17
Market Capitalization more info button	$1.9 billion

TTM: trailing 12 months

Trillium Therapeutics share dividends

We're not expecting Trillium Therapeutics to pay a dividend over the next 12 months.

Have Trillium Therapeutics's shares ever split?

Trillium Therapeutics's shares were split on a 1:30 basis on 19 November 2014 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Trillium Therapeutics shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Trillium Therapeutics shares which in turn could have impacted Trillium Therapeutics's share price.

Trillium Therapeutics share price volatility

Over the last 12 months, Trillium Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Trillium Therapeutics's is 1.9046. This would suggest that Trillium Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Trillium Therapeutics overview

As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc. , a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc.

Frequently asked questions

What percentage of Trillium Therapeutics is owned by institutions?
Currently 75.471% of Trillium Therapeutics shares are held by institutions. How many people work for Trillium Therapeutics?
Latest data suggests 33 work at Trillium Therapeutics. When does the fiscal year end for Trillium Therapeutics?
Trillium Therapeutics's fiscal year ends in December. Where is Trillium Therapeutics based?
Trillium Therapeutics's address is: 100 Cambridgepark Drive, Cambridge, MA, United States, 02140 What is Trillium Therapeutics's ISIN number?
Trillium Therapeutics's international securities identification number is: CA89620X5064 What is Trillium Therapeutics's CUSIP number?
Trillium Therapeutics's Committee on Uniform Securities Identification Procedures number is: 89620X100